Title |
Repurposed FDA-Approved drug sorafenib reduces replication of Venezuelan equine encephalitis virus and other alphaviruses
|
---|---|
Published in |
Antiviral Research, July 2018
|
DOI | 10.1016/j.antiviral.2018.07.005 |
Pubmed ID | |
Authors |
Lindsay Lundberg, Ashwini Brahms, Idris Hooper, Brian Carey, Shih-Chao Lin, Bibha Dahal, Aarthi Narayanan, Kylene Kehn-Hall |
Abstract |
The New World alphaviruses -Venezuelan, eastern, and western equine encephalitis viruses (VEEV, EEEV, and WEEV respectively) - cause a febrile disease that is often lethal in equines and children and leads to long-term neurological sequelae in survivors. Endemic to the Americas, epizootic outbreaks of the three viruses occur sporadically in the continental United States. All three viruses aerosolize readily, replicate to high titers in cell culture, and have low infectious doses. Additionally, there are no FDA-approved vaccines or therapeutics for human use. To address the therapeutic gap, a high throughput assay utilizing a luciferase reporter virus, TC83-luc, was performed to screen a library of commercially available, FDA-approved drugs for antiviral activity. From a group of twenty compounds found to significantly decrease luminescence, the carcinoma therapeutic sorafenib inhibited replication of VEEV-TC83 and TrD in vitro. Additionally, sorafenib inhibited replication of EEEV and two Old World alphaviruses, Sindbis virus and chikungunya virus, at 8 and 16 h post-infection. Sorafenib caused minimal toxicity in Vero cells, and coupled with a low EC50 value, yielded a selectivity index of >19. Mechanism of actions studies suggest that sorafenib inhibited viral translation through dephosphorylation of several key proteins, including eIF4E and p70S6K, leading to a reduction in viral protein production and overall viral replication. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 53 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 8 | 15% |
Student > Ph. D. Student | 7 | 13% |
Researcher | 6 | 11% |
Student > Bachelor | 5 | 9% |
Student > Doctoral Student | 4 | 8% |
Other | 10 | 19% |
Unknown | 13 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Immunology and Microbiology | 8 | 15% |
Biochemistry, Genetics and Molecular Biology | 8 | 15% |
Agricultural and Biological Sciences | 7 | 13% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 8% |
Arts and Humanities | 3 | 6% |
Other | 7 | 13% |
Unknown | 16 | 30% |